MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Wave Life Sciences Ltd. Operating Expenses 2011-2026 | WVE
Annual Operating Expenses Wave Life Sciences Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 258 M | 219 M | 181 M | 166 M | 168 M | 173 M | 224 M | 174 M | 106 M | 56.8 M | 19.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 258 M | 19.4 M | 159 M |
Quarterly Operating Expenses Wave Life Sciences Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 M | 61.5 M | 59 M | - | 56.2 M | 54.7 M | 47 M | - | 44.8 M | 45.6 M | 43.2 M | - | 39.2 M | 42.5 M | 39.8 M | - | 44 M | 42.6 M | 43.5 M | - | 37.9 M | 41.7 M | 54.2 M | 62.9 M | 57.1 M | 53.2 M | 51 M | 52.6 M | 42.7 M | 41.5 M | 37.2 M | 32.3 M | 27.7 M | 25.8 M | 20.6 M | 19.2 M | 17.6 M | 12.1 M | 7.95 M | 7.21 M | 4.99 M | 3.76 M | 3.49 M | 1.78 M | 1.35 M | 1.29 M | 968 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64 M | 968 K | 34.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Nanobiotix S.A.
NBTX
|
43.4 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | France |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.13 | -1.26 % | $ 315 M | USA |
 |
Codiak BioSciences
CDAK
|
92.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
16.6 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
17.3 M | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
14.7 M | - | -6.63 % | $ 13.9 M | USA |